Opdualag
What Opdualag is used for
Opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD L1 expression < 1%.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Opdualag
- Active substance
- relatlimab;nivolumab
- Disease area
- Melanoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01FY02
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Opdivo Qvantig, Opdivo, Opdualag
In India
- Nivolumab: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Opdualag used for?
Opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD L1 expression < 1%.
What is the active substance in Opdualag?
Opdualag contains relatlimab;nivolumab.
Who makes Opdualag?
The EU marketing authorisation holder is Bristol-Myers Squibb Pharma EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU